These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30808730)

  • 1. Urea Cycle Sustains Cellular Energetics upon EGFR Inhibition in EGFR-Mutant NSCLC.
    Pham-Danis C; Gehrke S; Danis E; Rozhok AI; Daniels MW; Gao D; Collins C; Paola JTD; D'Alessandro A; DeGregori J
    Mol Cancer Res; 2019 Jun; 17(6):1351-1364. PubMed ID: 30808730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells.
    Kim J; Hu Z; Cai L; Li K; Choi E; Faubert B; Bezwada D; Rodriguez-Canales J; Villalobos P; Lin YF; Ni M; Huffman KE; Girard L; Byers LA; Unsal-Kacmaz K; Peña CG; Heymach JV; Wauters E; Vansteenkiste J; Castrillon DH; Chen BPC; Wistuba I; Lambrechts D; Xu J; Minna JD; DeBerardinis RJ
    Nature; 2017 Jun; 546(7656):168-172. PubMed ID: 28538732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming.
    Thiagarajan PS; Wu X; Zhang W; Shi I; Bagai R; Leahy P; Feng Y; Veigl M; Lindner D; Danielpour D; Yin L; Rosell R; Bivona TG; Zhang Z; Ma PC
    Oncotarget; 2016 Dec; 7(50):82013-82027. PubMed ID: 27852038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
    Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
    Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldolase A promotes proliferation and G
    Fu H; Gao H; Qi X; Zhao L; Wu D; Bai Y; Li H; Liu X; Hu J; Shao S
    Cancer Commun (Lond); 2018 May; 38(1):18. PubMed ID: 29764507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma.
    Çeliktas M; Tanaka I; Tripathi SC; Fahrmann JF; Aguilar-Bonavides C; Villalobos P; Delgado O; Dhillon D; Dennison JB; Ostrin EJ; Wang H; Behrens C; Do KA; Gazdar AF; Hanash SM; Taguchi A
    J Natl Cancer Inst; 2017 Mar; 109(3):1-9. PubMed ID: 28376202
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Owusu-Ansah M; Guptan N; Alindogan D; Morizono M; Caldovic L
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic KRAS Induces Arginine Auxotrophy and Confers a Therapeutic Vulnerability to SLC7A1 Inhibition in Non-Small Cell Lung Cancer.
    Gai X; Liu Y; Lan X; Chen L; Yuan T; Xu J; Li Y; Zheng Y; Yan Y; Yang L; Fu Y; Tang S; Cao S; Dai X; Zhu H; Geng M; Ding J; Pu C; Huang M
    Cancer Res; 2024 Jun; 84(12):1963-1977. PubMed ID: 38502865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
    Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
    Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
    Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
    Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
    Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Yang Z; Zhang SL; Hu X; Tam KY
    Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment.
    Kawano Y; Iwama E; Tsuchihashi K; Shibahara D; Harada T; Tanaka K; Nagano O; Saya H; Nakanishi Y; Okamoto I
    Lung Cancer; 2017 Nov; 113():72-78. PubMed ID: 29110853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by
    Iommelli F; De Rosa V; Terlizzi C; Monti M; Panico M; Fonti R; Del Vecchio S
    Clin Cancer Res; 2018 Jul; 24(13):3126-3136. PubMed ID: 29618618
    [No Abstract]   [Full Text] [Related]  

  • 17. p53 inhibits the Urea cycle and represses polyamine biosynthesis in glioma cell lines.
    Zhao Y; Chen Y; Wei L; Ran J; Wang K; Zhu S; Liu Q
    Metab Brain Dis; 2023 Apr; 38(4):1143-1153. PubMed ID: 36745250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
    Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Glycolysis Supports Cell Survival in EGFR-Mutant Lung Adenocarcinoma by Inhibiting Autophagy-Mediated EGFR Degradation.
    Kim JH; Nam B; Choi YJ; Kim SY; Lee JE; Sung KJ; Kim WS; Choi CM; Chang EJ; Koh JS; Song JS; Yoon S; Lee JC; Rho JK; Son J
    Cancer Res; 2018 Aug; 78(16):4482-4496. PubMed ID: 29945964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.
    Torigoe H; Yamamoto H; Sakaguchi M; Youyi C; Namba K; Sato H; Shien K; Soh J; Suzawa K; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
    Carcinogenesis; 2018 May; 39(5):719-727. PubMed ID: 29546323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.